Eagle Pharmaceuticals Sees FY23 Adjusted EPS Of $4.20-$4.53 Vs. Consensus of $4.49
Expects 2023 Adjusted EBITDA of $74.0-$80.0 million
MindMed Reports Full-Year 2022 Financial Results, Highlighting Anxiety & Autism Studies
Clinical-stage biopharma company Mind Medicine (MindMed), Inc. (NASDAQ: MNMD) shared its financial results for the full year ended Dec. 31, 2022.
Numbers show solid stability:
Embraer Shares Gain After Q4 Results, Aircraft Deliveries Increase By 12.7% In FY22
Embraer SA (NYSE:ERJ) reported fourth-quarter FY22 revenue of $1.992 billion, an increase of 53% year-over-year, marginally beating the consensus of…
Why JinkoSolar Shares Are Sliding Today
JinkoSolar Holding Co., Ltd (NYSE:JKS) reported a fourth-quarter FY22 revenue growth of 85.5% year-on-year to $4.41 billion, beating the consensus of…
Oracle, Buckle And 3 Stocks To Watch Heading Into Friday
With US futures trading lower this morning on Friday, some of the stocks that may grab investor focus today are as follows:
Campbell Soup Gets Price Target Bumps By Analysts After Strong Q2 Results
Campbell Soup Co (NYSE: CPB) reported better-than-expected Q2 results and raised FY23 guidance.
Campbell reported quarterly sales growth of 12% year-on-year to $2.48 billion, beating the consensus of $2.44 billion. Adjusted EPS of $0.80 beat the analyst consensus of $0.74.
General Electric Stock Is Rising: What’s Driving The Action?
General Electric Co (NYSE: GE) shares are trading higher Thursday after the company updated guidance at its annual investor conference.
ANI Pharmaceuticals Sees FY23 Adjusted EPS of $2.09-$2.59 Vs. Consensus Of $2.62; Forecasts Revenues Of $360M-$385M Vs. $352.49M Estimate
2023 Cortrophin specific revenue guidance is between $80.0 million to $90.0 million, representing 92% to 116% growth as compared to $41.7 million recognized in